Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer

INTRODUCTION: Bruton’s tyrosine kinase (BTK) inhibitors have long been known in the treatment of B-cell malignancies. Recently, BTK inhibitors have also become promising novel treatment reagents for prostate cancer. The current study was designed to investigate expression of BTK in prostate cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Zhen, Ling, Lanlan, Qi, Lezhong, Chong, Yue, Xue, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231774/
https://www.ncbi.nlm.nih.gov/pubmed/32494164
http://dx.doi.org/10.2147/OTT.S245848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231774/
https://www.ncbi.nlm.nih.gov/pubmed/32494164
http://dx.doi.org/10.2147/OTT.S245848

Ejemplares similares